Nuclidium secures €84 million in Series B funding led by Angelini Ventures to advance its innovative copper-based radiopharmaceuticals for precision oncology.
Target Information
Nuclidium is innovating the precision oncology sector with its cutting-edge development of copper-based radiopharmaceuticals. These advanced therapeutics are designed to enhance the precision of cancer diagnosis and treatment, ensuring that patients receive optimal and targeted care. By integrating state-of-the-art technology into their products, Nuclidium aims to set a new standard in the medical industry.
With a focus on creating best-in-class solutions, the company is committed to improving accessibility and effectiveness in oncology. Their research and development efforts are centered around harnessing the unique properties of copper to provide high accuracy in theranostics, beneficial for both therapeutic and diagnostic applications in oncology.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in the Specific Country
The oncology market in the country is experiencing robust growth, driven by an increasing prevalence of cancer and a rising demand for innovative treatment options. As healthcare stakeholders become more aware of the effecti
Similar Deals
Angelini Ventures
invested in
NUCLIDIUM
in 2025
in a Series B deal
Disclosed details
Transaction Size: $90M